Concepedia
Statistics
Publications
8
Citations
2.1K
H-Index
Active since
2005
Affiliations
Massachusetts General Hospital(Current)
Harvard University
Ludwig Cancer Research
Center for Cancer Research
University of Oxford
Nadia Godin-Heymann is an author at Massachusetts General Hospital specializing in medicine, oncology, and molecular oncology.
Publications per year
2005–2015
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Eunice L. Kwak, Raffaella Sordella, Daphne W. Bell et al. · Proceedings of the National Academy of Sciences · 2005 · 952 citations
Medicine, Medicinal Chemistry, Pharmacology +13
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
Daphne W. Bell, Ira Gore, Ross A. Okimoto et al. · Nature Genetics · 2005 · 532 citations
Medicine, Genetics, Oncology +14
The T790M “gatekeeper” mutation in <i>EGFR</i> mediates resistance to low concentrations of an irreversible EGFR inhibitor
Nadia Godin-Heymann, Lindsey Ulkus, Brian W. Brannigan et al. · Molecular Cancer Therapeutics · 2008 · 205 citations · Full text
Medicine, Oncology, Pharmacology +14
<i>HOXB9</i> , a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis
Tetsu Hayashida, Fumiyuki Takahashi, Naokazu Chiba et al. · Proceedings of the National Academy of Sciences · 2009 · 164 citations · Full text
Medicine, Cancer Biology, Oncology +17
Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation
Nadia Godin-Heymann, Ianthe Bryant, Miguel N. Rivera et al. · Cancer Research · 2007 · 152 citations · Full text
Medicine, Oncology, Pharmacology +17
1–5 of 8